{"product_id":"ivesa-furmonertinib","title":"Ivesa  (Furmonertinib)","description":"\u003ch2\u003eAbout Furmonertinib\u003c\/h2\u003e\u003cp\u003eFurmonertinib Mesilate acts as an anti-cancer agent. It is formulated as tablets for oral route of administration. Furmonertinib is indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with positive EGFR T790M mutation.\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eFurmonertinib sold under the brand name Ivesa. \u003c\/li\u003e\n\u003cli\u003eFurmonertinib sold under the brand name 艾弗沙 in china.\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2 id=\"Takeda Receives Approval for FRUZAQLA (fruquintinib) in Japan for the Treatment of Unresectable Advanced or Recurrent Colorectal Cancer\" class=\"title !m-0 break-words text-dark-grey\" data-sb-field-path=\".title\"\u003e\u003cspan id=\"Approval\"\u003eApproval\u003c\/span\u003e\u003c\/h2\u003e\u003cp\u003eJune\/2022, Shanghai Allist Pharmaceuticals Co., Ltd. (stock code: 688578) announced that Furmonertinib had been approved by the National Medical Products Administration (NMPA) of China for use in the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion (19DEL) or exon 21 (L858R) substitution mutations.\u003c\/p\u003e\u003ch2\u003e\u003cspan id=\"Dosage\"\u003e\u003cspan id=\"Dosage_and_administration\"\u003eDosage\u003c\/span\u003e\u003c\/span\u003e\u003c\/h2\u003e\u003cp\u003eThe recommended dose of this product is 80 mg, taken orally once a day until disease progression or intolerable toxicity occurs.\u003c\/p\u003e\u003cp\u003eThis product should be taken on an empty stomach. Take this product at approximately the same time every day, swallow the whole tablet with water, do not crush or chew. If the patient misses a dose of this product and it is more than 12 hours before the next dose, the patient should take this product.\u003c\/p\u003e\u003ch3\u003eDosage adjustment\u003c\/h3\u003e\u003cp\u003eIf adverse events occur during the use of this product, the drug can be temporarily interrupted, the dose can be reduced, or the treatment with this product can be stopped according to the specific situation. If a reduction is required, the dose can be reduced to 40 mg, once a day.\u003c\/p\u003e","brand":"Allist Pharmaceuticals, China","offers":[{"title":"Default Title","offer_id":44797953605675,"sku":"RL2320241030285","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2024-10-2811.png?v=1787022208","url":"https:\/\/xomeds.com\/products\/ivesa-furmonertinib","provider":"XOMEDS","version":"1.0","type":"link"}